PEDIATRICS Vol. 94 No. 6 December 1994, pp. 841-846
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stenberg, A.
Right arrow Articles by Läckgren, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stenberg, A.
Right arrow Articles by Läckgren, G.

Desmopressin Tablets in the Treatment of Severe Nocturnal Enuresis in Adolescents

Arne Stenberg MD, PhD1 and Göran Läckgren MD, PhD1

1 Department of Pediatric Surgery, Section of Urology, Uppsala University Children's Hospital, Uppsala, Sweden

Background. In recent years the treatment of primary nocturnal enuresis (PNE) with desmopressin (DDAVP) has been promising. The route of administration until now had been intranasal, but because the tablets were introduced for the treatment of diabetes insipidus they have also become available for the treatment of PNE.

Objectives. To find the optimal dosage of desmopressin tablets and to compare desmopressin's efficacy with placebo in a group of adolescents with severe monosymptomatic enuresis. The long-term safety of desmopressin was also studied in the same group of patients.

Methods. The effect of oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP® tablets, Minirin®) was investigated in 25 adolescents (ages 11 to 21 years) with severe monosymptomatic nocturnal enuresis. The first part of the dose-ranging study comprised a single-blind dose titration period, followed by a double-blind, crossover efficacy period comparing desmopressin with placebo. The final part was an open long-term study consisting of two 12-week treatment periods. The efficacy of the drug was measured in reductions of the number of wet nights per week.

Results. During the first dose-titration period, the majority of the patients were given desmopressin 400 µg, and the number of wet nights decreased from a mean of 4.9 to 2.8. During the double-blind period, a significant reduction of wet nights was observed (1.8 vs 4.1 for placebo). During the two long-term periods, 48% and 53% of the patients could be classified as responders (0 to 1 wet night per week) and 22% and 23.5% as intermediate responders (2 to 3 wet nights per week). No weight gain was observed due to water retention. After cessation of the drug, 44% of the patients had a significant decrease in the number of wet nights.

Conclusions. Oral desmopressin has a clinically significant effect on patients with PNE, and therapy is safe when administered as long-term treatment.

Submitted on December 21, 1993
Accepted on March 29, 1994




This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
A. Dunlop
Meeting the Needs of Parents and Pediatric Patients: Results of a Survey on Primary Nocturnal Enuresis
Clinical Pediatrics, May 1, 2005; 44(4): 297 - 303.
[Abstract] [PDF]

Home page
 PediatricsHome page
T. Neveus, G. Lackgren, T. Tuvemo, and A. Stenberg
Osmoregulation and Desmopressin Pharmacokinetics in Enuretic Children
Pediatrics, January 1, 1999; 103(1): 65 - 70.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
G. A. Gimpel, W. J. Warzak, B. R. Kuhn, and J. N. Walburn
Clinical Perspectives in Primary Nocturnal Enuresis
Clinical Pediatrics, January 1, 1998; 37(1): 23 - 29.
[Abstract] [PDF]

Home page
 JWatch PsychiatryHome page
Oral Desmopressin for Enuretic Adolescents
Journal Watch Psychiatry, February 1, 1995; 1995(201): 16 - 16.
[Full Text]

Home page
 JWatch GeneralHome page
ORAL DESMOPRESSIN FOR ENURETIC ADOLESCENTS
Journal Watch (General), December 16, 1994; 1994(1216): 6 - 6.
[Full Text]